Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V565 Target Engagement in Ulcerative Colitis
NCT03705117Phase 1Completed
- Sponsor
- VHsquared Ltd.
- Start
- May 2017
- Primary completion
- Oct 2017
- Modality
- Antibody Conjugates, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of V565 in ulcerative colitis (UC), sponsored by VHsquared Ltd. Primary endpoints: Reduction of phosphorylation in mucosal biopsies at 7 days and Presence of drug in mucosal biopsies at 7 days. Started May 2017; status: completed.
02
Drugs
V565
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03705117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03705117.